Cynthia A. Moylan

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Stephen A. Harrison, Mustafa R. Bashir, Cynthia D. Guy et al. · The Lancet · 2019 · 733 citations

Metabolic Associated Steatohepatitis, Hepatology, Nonalcoholic Fatty Liver Disease +10

Relationship Between Methylome and Transcriptome in Patients With Nonalcoholic Fatty Liver Disease

Susan K. Murphy, Hyuna Yang, Cynthia A. Moylan et al. · Gastroenterology · 2013 · 386 citations · Full text

Metabolic Syndrome, Metabolic Associated Steatohepatitis, Hepatology +14

Disparities in Liver Transplantation Before and After Introduction of the MELD Score

Cynthia A. Moylan · JAMA · 2008 · 351 citations · Full text

Hepatic Gene Expression Profiles Differentiate Presymptomatic Patients With Mild Versus Severe Nonalcoholic Fatty Liver Disease

Cynthia A. Moylan, Herbert Pang, Andrew Dellinger et al. · Hepatology · 2013 · 317 citations · Full text

Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis

Wing‐Kin Syn, Steve S. Choi, Evaggelia Liaskou et al. · Hepatology · 2010 · 271 citations